Company family
Grindeks: medicine shortages
As of 2 Nov 2026, 7 Grindeks products have a reported shortage across 4 countries, covering 6 medicines.
Products short7rank #242 of 464
Medicines6active ingredients
Countries4/16
New in 90 days1-7 vs market pace
Typical duration5 monthsmedian so far
Manufacturing17%demand-driven 50%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Oxytocin | 2 | 13 Apr 2023 | Increased demand | 5/16 | |
| Bupivacaine | 1 | 15 Jun 2026 | Increased demand | 8/16 | |
| Lenalidomide | 1 | 15 May 2026 | Increased demand | 10/16 | |
| Metformin and Sitagliptin | 1 | 14 Jul 2026 | Manufacturing problem | 3/16 | |
| Ursodeoxycholic Acid | 1 | 2 Sep 2025 | Distribution or logistics | 7/16 | |
| Zopiclone | 1 | 5 Oct 2026 | Regulatory or licensing | 3/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.